Natural product-based therapy for Metastatic tumors: Sulindac, an anti-inflammatory drug, increases the expression of tumor suppressor CCM1/KRIT1 via down regulation of its target gene, 1/March/2015, 10.07 am

Natural product-based therapy for Metastatic tumors: Sulindac, an anti-inflammatory drug, increases the expression of tumor suppressor CCM1/KRIT1 via down regulation of its target gene, 1/March/2015, 10.07 am

Natural product-based therapy for Metastatic tumors: Sulindac, an anti-inflammatory drug, increases the expression of tumor suppressor CCM1/KRIT1 via down regulation of its target gene, 1/March/2015, 10.07 am 150 150

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Natural product-based therapy for Metastatic tumors: Sulindac, an anti-inflammatory drug, increases the expression of tumor suppressor CCM1/KRIT1 via down regulation of its target gene, 1/March/2015, 10.07 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that Sulindac, by suppressing the expression of its target geneit may increase the expression of CCM1/KRIT1. Thereby, it may inhibit tumor progressionThus, pharmacological formulations encompassing “Sulindac or its analogues”  may be used to inhibit the progression of tumors.

Amount: $ 300

Undisclosed information: How Sulindac increases the expression of CCM1/KRT1

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org